# Solstice Advanced Materials Inc.: overview

SOLS · Nasdaq · CIK 2064953 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sols.md) · [Financials](/companies/sols/financials.md) · [Filings](/companies/sols/filings.md) · [Insiders](/companies/sols/insiders.md)

Latest reported revenue: [$1.15bn](/filings/0002064953-26-000087.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0002064953-26-000087).

## Last eight quarters

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [907](/filings/0002064953-25-000018.md) | [913 d](/filings/0002064953-26-000008.md) | [897](/filings/0002064953-26-000047.md) | [1,033](/filings/0002064953-26-000087.md) | [969](/filings/0002064953-25-000018.md) | [987 d](/filings/0002064953-26-000008.md) | [991](/filings/0002064953-26-000047.md) | [1,148](/filings/0002064953-26-000087.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [16.8%](/filings/0002064953-25-000018.md) | [14.6% d](/filings/0002064953-26-000008.md) | [14.9%](/filings/0002064953-26-000047.md) | [9.4%](/filings/0002064953-26-000087.md) | [(3.6%)](/filings/0002064953-25-000018.md) | [4.2% d](/filings/0002064953-26-000008.md) | [8.6%](/filings/0002064953-26-000047.md) | [10.4%](/filings/0002064953-26-000087.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.85](/filings/0002064953-26-000047.md) | [0.61](/filings/0002064953-26-000087.md) | not reported | not reported | [0.53](/filings/0002064953-26-000047.md) | [0.75](/filings/0002064953-26-000087.md) |
| Free cash flow | $m | not reported | [180 d](/filings/0002064953-26-000008.md) | [98.0](/filings/0002064953-26-000047.md) | [74.0 d](/filings/0002064953-26-000087.md) | [(131) d](/filings/0002064953-25-000018.md) | [78.0 d](/filings/0002064953-26-000008.md) | [124](/filings/0002064953-26-000047.md) | [124 d](/filings/0002064953-26-000087.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY (2023-12-31) | FY (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: |
| Revenue | $m | [3,649](/filings/0002064953-26-000008.md) | [3,770](/filings/0002064953-26-000008.md) | [3,886](/filings/0002064953-26-000008.md) |
| Gross margin | % | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported |
| Net margin | % | [17.0%](/filings/0002064953-26-000008.md) | [15.8%](/filings/0002064953-26-000008.md) | [6.1%](/filings/0002064953-26-000008.md) |
| Diluted EPS | $ per share | [3.91](/filings/0002064953-26-000008.md) | [3.74](/filings/0002064953-26-000008.md) | [1.49](/filings/0002064953-26-000008.md) |
| Free cash flow | $m | [461](/filings/0002064953-26-000008.md) | [546](/filings/0002064953-26-000008.md) | [119](/filings/0002064953-26-000008.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sols/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.41bn | 15,931,864 |  | Added +955,263 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $703.7m | 7,942,655 |  | Added +14,261 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $635.6m | 7,173,963 |  | Added +47,450 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $448.6m | 5,063,616 |  | Added +93,731 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $297.3m | 3,355,801 |  | Added +905,732 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $291.7m | 3,291,746 |  | Added +870,370 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $255.2m | 2,880,302 |  | Added +234,065 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $250.9m | 2,831,377 |  | Added +274,730 |
| [Castle Hook Partners LP](/funds/1687241.md) | 2026-06-30 | $197.3m | 2,226,617 |  | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $196.0m | 2,211,844 |  | Reduced −459,740 |

## Recent filings

[All 155 filings](/companies/sols/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-27 | 17:18 ET | [8-K](/filings/0001104659-26-102503.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-102503 |
| 2026-07-30 | 16:04 ET | [10-Q](/filings/0002064953-26-000087.md) | Quarterly report, period 2026-06-30 | 0002064953-26-000087 |
| 2026-07-30 | 06:02 ET | [8-K](/filings/0002064953-26-000085.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002064953-26-000085 |
| 2026-07-27 | 09:00 ET | [8-K](/filings/0001104659-26-086878.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-086878 |
| 2026-07-20 | 08:00 ET | [8-K](/filings/0001213900-26-079407.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-079407 |
| 2026-07-17 | 07:14 ET | [8-K](/filings/0002064953-26-000081.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0002064953-26-000081 |
| 2026-07-09 | 08:34 ET | [8-K/A](/filings/0001213900-26-076547.md) | 9.01 Financial statements and exhibits | 0001213900-26-076547 |
| 2026-07-07 | 17:31 ET | [8-K](/filings/0001213900-26-075618.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-075618 |
| 2026-07-06 | 09:27 ET | [8-K](/filings/0001213900-26-075267.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-075267 |
| 2026-05-22 | 16:16 ET | [8-K](/filings/0001104659-26-065732.md) | 5.07 Shareholder vote results | 0001104659-26-065732 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0002064953-26-000008.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f6941d3a-b4d4-4b0f-af60-61ddaf4e6488)

## About the filer

- CIK: 2064953
- Tickers: SOLS
- Exchange: Nasdaq
- SIC code: 2800 Chemicals & Allied Products
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.